Sinopsis
"Not So Different," a podcast from The Center for Biosimilars, brings you expert viewpoints from physicians, pharmacists, patients, developers, and other stakeholders in the complex world of biosimilar therapies.
Episodios
-
S4 Ep3: The Race to the Top: Does China Have What it Takes?
07/02/2021 Duración: 05minYou can read more about China’s market by clicking here or here. For information on Bio-Thera, click here. For information on Shanghai Henlius Biotech, click here.
-
S4 Ep2: Why You Should Keep Your Eye on Ophthalmology Biosimilars
24/01/2021 Duración: 07minTo read more on Dr Oskouei's contributor piece, click here.
-
S4 Ep1: Charles Bennett, MD, PhD, Discusses Why the FTC Needs to Join the Effort to Improve the Biosimilar Market
10/01/2021 Duración: 09minTo read more about Bennett's study, click here.
-
S3 Ep32: Sean McGowan on What’s in Store for Biosimilars in 2021 and Beyond
06/12/2020 Duración: 10minTo watch the full first part of this interview, click here. To watch part 2 of this interview, click here. To watch part 3 of this interview, click here.
-
S3 Ep31: A Trio of Experts’ Take on What Needs to Change to Boost Biosimilar Adoption
29/11/2020 Duración: 08minTo learn more about biosimilar barriers, click here. To learn more about the US Oncology Network, click here. To learn more about McKesson, click here.
-
S3 Ep30: Kathy Oubre On What Practices Can Learn About the Benefits of Implementing Biosimilars
15/11/2020 Duración: 09minTo learn more about the COA's virtual Payer Exchange Summit on Oncology Payment Reform, click here. To learn more about Pontchartrain Cancer Center, click here.
-
S3 Ep29: Steven C. Hill, PhD, Discusses Rebates and Specialty Drug Spending
08/11/2020 Duración: 12minTo learn more about this study, click here.
-
S3 Ep28: Nancy Globus, PharmD, on Whether Comparative Efficacy Trials are Necessary
25/10/2020 Duración: 07minTo learn more about the study mentioned in this podcast, click here. To learn more about the United Kingdom's stance on comparative efficacy trials, click here.
-
S3 Ep27: Kathy Oubre on What Oncology Practices Lacked During the Pandemic
18/10/2020 Duración: 14minTo learn more about COVID-19’s impact on biosimilars, check out our ebook here.
-
S3 Ep26: Kanika Monga, MD, and Angus Worthing, MD, Discuss ACR Survey on Biosimilars and COVID-19
11/10/2020 Duración: 12minTo learn more about the ACR’s survey, click here. To learn more about COVID-19’s impact on biosimilars, check out our ebook here.
-
S3 Ep25: Wayne Winegarden, PhD, On Why Importing Drugs From Canada Is a Bad Idea
04/10/2020 Duración: 08minTo read more on Wayne’s thoughts of this plan, click here. To learn more about the Safe Importation Action Plan, click here. To learn more about President Trump’s executive orders, click here.
-
S3 Ep24: Julie Kennerly-Shah, PharmD, on How Biosimilars Can Help Curb COVID-19's Impact
27/09/2020 Duración: 10minTo learn more about COVID-19's impact on biosimilars, click here. To learn more about biosimilar education, click here. To learn more about step therapy, click here. To learn more about payer interference on preferred drugs, click here.
-
S3 Ep23: Rep Grothman on His Bill to Make Biosimilar Insulins Interchangeable
20/09/2020 Duración: 09minTo learn more about HR 8190, click here. To learn more about the regulatory transition of insulin under the BPCIA, click here. To learn more about interchangeability designations, click here.
-
S3 Ep22: Alex Moulson on How Companies Choose Which Biosimilars to Produce
13/09/2020 Duración: 09minTo check out more of our coverage of Polpharma Biologics, click here. To learn more about Polpharma's natalizumab clinical trial, click here. To learn about Polpharma Biologics recent integration efforts, click here. To learn more about Polpharma Biologics, click here.
-
S3 Ep21: Cheryl Larson on How Employers Can Get Biosimilars Added to Their Health Plan
06/09/2020 Duración: 10minTo learn more about MBGH's call to action for employers, click here. To learn more about MBGH's biosimilars report, click here. To learn more about Midwest Business Group on Health, click here.
-
S3 Ep20: Jonathan Sweeting on Aybintio's European Approval
30/08/2020 Duración: 09minTo learn more about the EC's approval of Aybintio, click here. To learn more about Samsung Bioepis, click here.
-
S3 Ep19: Nancy Globus, PharmD, on the Effect of Biosimilar Suffixes
23/08/2020 Duración: 06minTo learn more about biosimilar naming, click here. Click here to learn more about the ACMA.
-
S3 Ep18: Carter Thorne, MD, Discusses Biosimilar Switching in Canada
16/08/2020 Duración: 07minTo learn more about Canadian switching policies, click here.
-
S3 Ep17: Sizing Up European Biosimilar Competition
09/08/2020 Duración: 09minTo check out the scorecard, click here. To learn more about Medicines for Europe, click here.
-
S3 Ep16: Dorothy McCabe, PhD, Discusses How to Combat Biosimilar Misinformation
02/08/2020 Duración: 07minTo learn more about the opinion piece McCabe co-authored, click here. To learn more about Boehringer Ingelheim, visit boehringer-ingelheim.com.